Risperidone: Clinical safety and efficacy in schizophrenia

R. L. Borison, A. P. Pathiraja, B. I. Diamond, R. C. Meibach

Research output: Contribution to journalArticle

246 Scopus citations

Abstract

Risperidone represents a unique pharmacology of potent antagonism of both serotonin2 and dopamine2 receptors. In a randomized, parallel-group, double-blind trial of risperidone vs. haloperidol and placebo in 36 schizophrenic patients in acute exacerbation, risperidone showed a quicker onset of antipsychotic activity than did haloperidol. Risperidone treatment was statistically superior to placebo, with a trend toward superiority to haloperidol. Risperidone did not differ from placebo on assessment scales of extrapyramidal side effects, but produced significantly less than did haloperidol. There were no major adverse reactions associated with risperidone use, but it was noted to reduce the signs of tardive dyskinesia. This study suggests that risperidone may offer a superior side-effect profile, and possibly greater efficacy, than a standard neuroleptic such as haloperidol.

Original languageEnglish (US)
Pages (from-to)213-218
Number of pages6
JournalPsychopharmacology Bulletin
Volume28
Issue number2
StatePublished - Jan 1 1992

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Risperidone: Clinical safety and efficacy in schizophrenia'. Together they form a unique fingerprint.

  • Cite this

    Borison, R. L., Pathiraja, A. P., Diamond, B. I., & Meibach, R. C. (1992). Risperidone: Clinical safety and efficacy in schizophrenia. Psychopharmacology Bulletin, 28(2), 213-218.